0.05),經(jīng)治療后各組上述指標(biāo)與治療前比差異有統(tǒng)計學(xué)意義(P<0.05)。治療后聯(lián)合組BNP下降更為明顯(P<0.05),LVEF升高更明顯(P<0.05),6WMT增加更明顯(P<0.05)。結(jié)論 注射用益氣復(fù)脈(凍干)聯(lián)合重組人腦利鈉肽治療心房顫動伴慢性心力衰竭患者可明顯提高患者臨床總有效率,對患者LVEF、6MWT及BNP有明顯的改善作用。;Objective To investigate the clinical efficacy of Yiqi Fumai Lyophilized Injection combined with recombinant human brain natriuretic peptide in treatment of atrial fibrillation with chronic heart failure. Methods Total 203 patients with atrial fibrillation and chronic heart failure hospitalized in the Department of Cardiology, Wudang Hospital Affiliated to Guizhou Medical University from September 2018 to December 2020 were collected retrospectively. According to different treatment methods, the patients were divided into control group (n=97) and combined group (n=106). All patients were treated with routine anti heart failure treatment. The patients in the control group were given recombinant human brain natriuretic peptide for injection on the basis of routine treatment, and the first dose was 0.15 μg/kg intravenously, followed by 0.075 μg/(kg·min) for 72 hours. On the basis of the treatment of the control group, patients in the combined group added 5.2 g of Yiqi Fumai Lyophilized Injection for injection into 250 mL of 5% glucose injection, intravenous drip, once a day, for 14 days. One month after treatment, the curative effect of the two groups were evaluated and brain natriuretic peptide (BNP), left ventricular ejection fraction (LVEF) and 6-minute walking distance (6MWT) were measured. The total clinical effective rates of the two groups were compared by binary logistic regression analysis. Results The total effective rate of the combined group was 81.1%, which was significantly higher than 67.0% in the control group (P<0.05). Before treatment, there was significant difference in BNP, LVEF and 6MWT between the two groups (P<0.05). Before treatment, there was no significant difference in BNP, LVEF, and 6MWT between the two groups of patients (P>0.05). After treatment, the above indexes in each group were significantly different from those before treatment (P<0.05). There was significant difference in BNP level between the two groups after treatment, and BNP decreased more significantly in the combined group after treatment (P<0.05). There was significant difference in LVEF between the two groups after treatment, and LVEF increased more significantly in the combined group (P<0.05). There was significant difference in 6MWT between the two groups after treatment, and the increase of 6wmt in the combined group was more obvious after treatment (P<0.05). Conclusion Yiqi Fumai Lyophilized Injection combined with recombinant human brain natriuretic peptide can significantly improve the total clinical effective rate of patients with atrial fibrillation and chronic heart failure, and can significantly improve LVEF, 6MWT and BNP."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2021年第44卷第11期 >2021,44(11):2487-2492. DOI:10.7501/j.issn.1674-6376.2021.11.031
上一篇 | 下一篇

注射用益氣復(fù)脈(凍干)聯(lián)合重組人腦利鈉肽治療心房顫動伴慢性心力衰竭的臨床研究

Clinical study of Yiqi Fumai Lyophilized Injection combined with recombinant human brain natriuretic peptide in treatment of atrial fibrillation with chronic heart failure

發(fā)布日期:2021-11-10
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031